Novo Resources Corp. (NVO.V) Stock Price, News & Analysis (CVE:NVO) C$2.38 -0.01 (-0.42%) (As of 12/31/2020) Add Compare Share Share Today's RangeC$2.37▼C$2.4450-Day RangeC$2.38▼C$2.3852-Week RangeC$1.41▼C$4.16Volume311,570 shsAverage Volume273,252 shsMarket CapitalizationC$548.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A About Novo Resources Corp. (NVO.V) Stock (CVE:NVO)Novo Resources Corp., together with its subsidiaries, engages in evaluating, acquiring, and exploring natural resource properties in Canada, Australia, and the United States. It primarily explores for gold deposits. The company primarily focuses on the Egina and Beatons Creek projects in the Pilbara region of Western Australia. It also holds interest in the Mt. Elsie project that consists of three exploration licenses covering an area of approximately 19 square kilometers located in the north-east of Nullagine, Western Australia. The company was formerly known as Galliard Resources Corp. and changed its name to Novo Resources Corp. in June 2011. Novo Resources Corp. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More NVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVO Stock News HeadlinesDecember 6, 2023 | msn.comNovo Nordisk’s Wegovy beats older obesity meds in drug adherenceDecember 6, 2023 | americanbankingnews.comNovo Resources Corp. (NVO.V) (CVE:NVO) Shares Down 0.4% December 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 1, 2023 | msn.comCompounded Wegovy Matters Sink Novo Nordisk (NYSE:NVO)November 30, 2023 | msn.comNovo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffsNovember 30, 2023 | msn.comNovo Nordisk sues Florida pharmacies for selling compounded Wegovy with impuritiesNovember 27, 2023 | msn.comNovo Nordisk CEO: Willing to be "flexible" on Wegovy pricing schemes - FTNovember 24, 2023 | msn.comNovo Nordisk (NYSE:NVO) Set to Introduce Wegovy in AsiaDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 24, 2023 | msn.comNovo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply CrunchNovember 23, 2023 | marketwatch.comWegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in FranceNovember 14, 2023 | msn.comNovo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'November 14, 2023 | msn.comNovo Nordisk's Wegovy may not secure Medicare approval for heart - Deutsche BankNovember 14, 2023 | finance.yahoo.comSuccessful RC Drill Program Completed at Nunyerry NorthNovember 13, 2023 | msn.comNovo Nordisk's Wegovy reduces risk of serious heart problems by 20%, study showsNovember 13, 2023 | msn.comNovo Nordisk's (NVO) Wegovy Positive in Cardiovascular StudyNovember 13, 2023 | barrons.comEuropean Stocks Climb, Novo Nordisk Gains on Wegovy DataNovember 10, 2023 | msn.comNovo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand productionNovember 9, 2023 | msn.comPeople Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk BillionsNovember 3, 2023 | msn.comNovo Nordisk flags big 2024 sales boost despite Wegovy curbsNovember 2, 2023 | msn.comNovo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a monthNovember 2, 2023 | msn.comWeight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk saysNovember 2, 2023 | msn.comWegovy could receive expanded FDA approval within six months, Novo Nordisk saysNovember 1, 2023 | msn.comNovo Nordisk Reports Earnings Thursday. It’s All About Weight-Loss Drugs.November 1, 2023 | reuters.comExclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - sourceOctober 16, 2023 | msn.comNovo Nordisk to buy hypertension drug candidate for up to $1.3BOctober 16, 2023 | msn.comNovo Nordisk Buys Hypertension Drug in $1.3 Billion DealSee More Headlines Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Resources Corp. (NVO.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE Industry Industrial Metals & Minerals Sub-IndustryN/A SectorBasic Materials Current SymbolCVE:NVO CUSIPN/A CIKN/A Webwww.novoresources.com Phone604-562-4854FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio11.62 Current Ratio2.78 Quick Ratio2.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.22 per share Price / Cash Flow10.77 Book ValueC$1.38 per share Price / Book1.72Miscellaneous Outstanding Shares230,354,000Free FloatN/AMarket CapC$548.24 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Quinton Todd Hennigh (Age 53)Chairman & Pres Comp: $364.38kMr. Robert HumphrysonCEO & DirectorMr. Ronan Sabo-WalshCFO & Corp. Sec.Mr. Leonidas Karabelas (Age 41)VP of Corp. Communications Ms. Kas De LucaGen. Mang. of ExplorationMr. Alwin van RoijSr. Exploration GeologistMore ExecutivesKey CompetitorsKlondex MinesTSE:KDXGT GoldCVE:GTTNoront ResourcesCVE:NOTMaverix MetalsCVE:MMXMcEwen MiningTSE:MUXView All CompetitorsInsidersMichael Charles BarrettSold 2,500 sharesTotal: C$714.00 ($0.29/share)Quinton Todd HennighBought 33,000 shares on 12/21/2022Total: C$9,240.00 ($0.28/share) NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed in 2023? Novo Resources Corp. (NVO.V)'s stock was trading at C$2.38 at the start of the year. Since then, NVO stock has increased by 0.0% and is now trading at C$2.38. View the best growth stocks for 2023 here. What other stocks do shareholders of Novo Resources Corp. (NVO.V) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Resources Corp. (NVO.V) investors own include Pretium Resources (PVG), Ivanhoe Mines (IVN), Pretium Resources (PVG), Gold Standard Ventures (GSV), Harmony Gold Mining (HMY), First Majestic Silver (AG), Yamana Gold (AUY), Barrick Gold (GOLD) and Alexco Resource (AXU). How do I buy shares of Novo Resources Corp. (NVO.V)? Shares of NVO stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:NVO) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Resources Corp. (NVO.V) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.